Embryo-fetal safety evaluation of ondansetron in rats

Página do item simplificado
dc.contributor.authorReis, Ana Carolina Casali [UNESP]
dc.contributor.authorJorge, Bárbara Campos [UNESP]
dc.contributor.authorda Silva Moreira, Suyane [UNESP]
dc.contributor.authorStein, Júlia [UNESP]
dc.contributor.authorPerdão, Carolina Barizan [UNESP]
dc.contributor.authorde Matos Manoel, Beatriz
dc.contributor.authorArena, Arielle Cristina [UNESP]
dc.contributor.institutionUniversidade Estadual Paulista (UNESP)
dc.contributor.institutionFederal University of Grande Dourados
dc.date.accessioned2023-07-29T13:40:43Z
dc.date.available2023-07-29T13:40:43Z
dc.date.issued2023-04-01
dc.description.abstractBackground: Ondansetron is a 5HT3 receptor antagonist, used to mitigate the effects of nausea and vomiting after chemotherapy or surgery. Since nausea and vomiting are common experiences during the first trimester of pregnancy, this antiemetic has been the main drug used during this period. Methods: To evaluate the effects of ondansetron on the embryo-fetal development, which are still very contradictory, pregnant rats were exposed to therapeutic doses of ondansetron (1.7 or 2.5 mg/kg) daily, from gestational day (GD) 6 to 15. Results: No clinical signs of toxicity were observed in dams during the treatment. Although the hemato-biochemical parameters were similar among the groups, histological changes, as well as a reduction in the weight of kidney were found in the treated dams. After fetal examination, no visceral and skeletal abnormalities were observed in treated fetuses. Conclusion: In conclusion, therapeutic doses of ondansetron have low teratogenic potential in rats. These data provide important information about the drug safety during pregnancy.en
dc.description.affiliationDepartment of Structural and Functional Biology Institute of Biosciences of Botucatu Universidade Estadual Paulista – UNESP, São Paulo
dc.description.affiliationCollege of Health Science Federal University of Grande Dourados, Mato Grosso do Sul
dc.description.affiliationCenter of Toxicological Assistance (CEATOX) Institute of Biosciences of Botucatu Universidade Estadual Paulista – Botucatu (UNESP), São Paulo
dc.description.affiliationUnespDepartment of Structural and Functional Biology Institute of Biosciences of Botucatu Universidade Estadual Paulista – UNESP, São Paulo
dc.description.affiliationUnespCenter of Toxicological Assistance (CEATOX) Institute of Biosciences of Botucatu Universidade Estadual Paulista – Botucatu (UNESP), São Paulo
dc.description.sponsorshipFundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)
dc.description.sponsorshipIdFAPESP: 2020/08745-9
dc.format.extent605-613
dc.identifierhttp://dx.doi.org/10.1002/bdr2.2154
dc.identifier.citationBirth Defects Research, v. 115, n. 6, p. 605-613, 2023.
dc.identifier.doi10.1002/bdr2.2154
dc.identifier.issn2472-1727
dc.identifier.scopus2-s2.0-85147528658
dc.identifier.urihttp://hdl.handle.net/11449/248319
dc.language.isoeng
dc.relation.ispartofBirth Defects Research
dc.sourceScopus
dc.subjectkidney
dc.subjectnausea and vomiting
dc.subjectorganogenesis
dc.subjectrats
dc.subjectsafety
dc.subjectteratogenicity
dc.titleEmbryo-fetal safety evaluation of ondansetron in ratsen
dc.typeArtigo
unesp.author.orcid0000-0002-2373-9399[7]

Arquivos

Coleções

Botucatu - CEATOX - Centro de Assistência Toxicológica